WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Helen Louise CollinsMed2026-10-195,000$2.48
$12.40kBuy
Helen Louise CollinsMed2026-10-195,000$38.47
$192.34kSell
Benjamin HohlCFO2026-10-196,018$14.85
$89.37kBuy
Benjamin HohlCFO2026-10-196,018$38.48
$231.54kSell
J. Scott GarlandDirector2026-10-0113,000$15.47
$201.11kBuy
J. Scott GarlandDirector2026-10-0113,000$46.67
$606.72kSell
Benjamin HohlCFO2026-09-173,982$14.85
$59.13kBuy
Benjamin HohlCFO2026-09-173,535$50.03
$176.85kSell
Benjamin HohlCFO2026-09-172,194$50.72
$111.27kSell
Benjamin HohlCFO2026-09-17289$51.49
$14.88kSell

1 of 10

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC12.40%9,087,504$409.66MInsider
David P. Bonita11.46%8,398,136$378.59MInsider
5am Partners VI LLC11.11%8,142,154$367.05MInsider
Rishi Gupta10.85%7,951,463$358.45MInsider
Ra Capital Management LP4.88%3,576,813$161.24MInsider
New Enterprise Associates 14 LP3.56%2,611,050$117.71MInsider
Mark Chin3.20%2,344,072$105.67MInsider
Braden Michael Leonard2.73%1,997,774$90.06MInsider
Pfizer Inc2.13%1,557,722$70.22MInsider
Barbara Dalton2.13%1,557,722$70.22MInsider

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN0.11%80.98%Net SellingNet Selling
TARS0.11%39.11%Net SellingNet Selling
TLX0.00%7.54%Net BuyingNet Buying
CELC0.12%22.15%Net SellingNet Buying
AMLX0.10%50.21%Net SellingNet Selling
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 0.11% institutional shareholders, 80.98% Enliven Therapeutics insiders, and 18.91% retail investors. Orbimed Advisors LLC is the largest individual Enliven Therapeutics shareholder, owning 9.09M shares representing 12.40% of the company. Orbimed Advisors LLC's Enliven Therapeutics shares are currently valued at $409.66M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.